메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

BERLIN, Oct. 20, 2025 -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement. Since 2016, Hengrui has presented pioneering research at the ESMO Annual Congress for ten consecutive years. This year, the company unveiled 46 s
- 김갑성 기자
- 2025-10-20 14:20
From Corporate Social Responsibility To Global Consensus: Chery's "Ride Green Life" Unites the World for a Sustainable Future

WUHU, China, Oct. 20, 2025 -- As the global automotive industry accelerates toward a green, low-carbon future, corporate social responsibility has evolved — now defined by sustainable practices fostering harmony between people, society, and nature. As a globally recognized automotive brand, Chery continues to drive this vision through long-term, tangible actions uniting technology, humanity, and nature in balance. On October 20, the third "Ride Green Life" Charity cycling event officially took place along the Yangtze River in Wuhu. As a key event of the 2025 Chery Internation
- 황정호 기자
- 2025-10-20 14:04
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global access to plasma-derived medicines and strengthens its ability to meet the increasing demand for life-saving plasma therapies worldwide. Prothya Biosolutions is one of Europe's leading plasma fractionators, operating major facilities in Amsterdam and Brussels, along with plasma collection centr
- 김갑성 기자
- 2025-10-20 14:00
어코드 플라스마, 프로시아 바이오솔루션스 인수로 글로벌 혈장 치료 역량 강화

런던, 2025년 10월 20일 -- 인타스 파마슈티컬스(Intas Pharmaceuticals)의 자회사인 어코드 플라스마(Accord Plasma B.V.)가 20일 프로시아 바이오솔루션스 벨기에(Prothya Biosolutions Belgium BV) 및 그 자회사들의 인수를 성공적으로 완료했다고 밝혔다. 이번 전략적 조치를 통해 어코드는 혈장분획제제(plasma-derived medicinal products•PDMPs)에 대한 글로벌 접근성을 개선한다는 자사의 의지를 한층 더 강화하고, 전 세계적으로 증가하는 생명 구호 혈장 치료제 수요를 충족시킬 수 있는 능력을 높이게 됐다. 프로시아 바이오솔루션스는 유럽을 선도하는 혈장분획업체 중 하나로, 암스테르담과 브뤼셀에 주요 시설을 운영하며, 헝가리 전역에 혈장 수집 센터를 보유하고 있다. 회사는 약 1200명의 숙련된 전문가를 고용하고 있다. 전 세계적 혈장 치료 접근성 확대 프로시아와의 통합으로 어코드는 혈장 역량이 크게 향상됐다. 유럽에서 입증된 프로시아의 전문성과 인타스가 인도에서 확보한 대규모 분획 인프라를 결합함으로써 다양한 지
- 김갑성 기자
- 2025-10-20 14:00
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor receptor 2 (HER2)-directed ADC trastuzumab botidotin (also known as A166) trastuzumab botidotin versus trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic BC was presented as an oral report by Professor Xichun Hu from Fudan University Shanghai Cancer Center (Presentation # LBA2
- 김갑성 기자
- 2025-10-20 13:59
MILESEEY GenePro G1 Named to TIME's "The Best Inventions of 2025: Special Mentions"

The first "GPS + Laser" hybrid rangefinder redefining how golfers see and play the game. CITY OF INDUSTRY, Calif., Oct. 20, 2025 -- MILESEEY Golf proudly announces that its groundbreaking hybrid rangefinder, the GenePro G1, has been featured in TIME's "The Best Inventions of 2025: Special Mentions."Recognized for its innovative integration of AMOLED full-color touchscreen and built-in global course mapping, the GenePro G1 stands out as a true "GPS + Laser" hybrid that brings a smarter, faster, and more intuitive experience to every golfer's round.&
- 황정호 기자
- 2025-10-20 13:57
Chengdu CATANIA's Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.

CHENGDU, China, Oct. 20, 2025 -- A news report from CNS: Recently, a wave of discerning homebuyers from different cities has been converging on Chengdu CATANIA. International elites from New York, London, Tokyo, Singapore, Hong Kong, Vancouver, and other world-class major cities have found a common ground in Chengdu. The global acclaim for Chengdu CATANIA goes far beyond a simple purchase. It is an affirmation of its international standing. This recognition stems from its core advantages—an unrivaled location, top-tier amenities, and a deeply integrated art gene. These q
- 김장윤(JASON KIM) 기자
- 2025-10-20 13:56
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the indication of monotherapy for the treatment of HER2-positive advanced colorectal cancer (CRC) in patients who have failed prior treatments with oxaliplatin, fluorouracil and irino
- 김갑성 기자
- 2025-10-20 13:21
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025

SUZHOU, China, Oct. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colorectal cancer (mCRC), along with the confirmatory study design of the phase III study of JSKN003 versus physician's choice of chemotherapy in platinum-resistant ovarian cancer (PROC) were presented as posters at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) from October 17 to 21, 2025,
- 김갑성 기자
- 2025-10-20 13:15
1664 ANNOUNCES FIRST-EVER ASIA-WIDE ARTIST COLLABORATION WITH FRENCH ARTIST CAMILLE WALALA

A Joyful, Design-led Partnership to Celebrate the Festive Season HONG KONG, Oct. 20, 2025 -- This festive season, 1664 is excited to announce its first-ever festive artist collaboration across Hong Kong, mainland China, Singapore, Malaysia, and Vietnam with celebrated French artist Camille Walala. Bringing a modern twist to the traditional holiday season that encapsulates Christmas and Lunar New Year, 1664 will be introducing limited-edition designs and upbeat experiences from October 2025 onwards. This partnership exemplifies Carlsberg Group's strategy to transform convivial m
- 황정호 기자
- 2025-10-20 12:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-10-29_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 29일 10시 40분